ALPA62.19

Alpa Laboratories Limited

· Pharma & Health
₹ CrorePeersBALPHARMAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹131 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)79.3291.0476.9476.94
Receivable Days (DSO)138.97151.99140.85140.85
Payable Days (DPO)68.3696.48102.6689.15
Cash Conversion Cycle (days)149.93146.55115.13128.64
Working Capital Turnover0.820.780.670.70
Asset Turnover0.600.510.440.44
Cash Conversion (CFO/Net Income)0.220.360.750.75
CFO/EBITDA0.451.483.243.24
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.